• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Vazzano Joseph Walter

    1/24/25 4:13:53 PM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Vazzano Joseph Walter

    (Last) (First) (Middle)
    24 SCHOOL ST.
    2ND FLOOR

    (Street)
    BOSTON MA 02108

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Allarity Therapeutics, Inc. [ ALLR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/22/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options $1.01 01/22/2025 A 25,000 01/22/2025(1) 01/22/2030 Common Stock 25,000 $0 25,000 D
    Explanation of Responses:
    1. The stock options, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
    /s/ Joseph Vazzano 01/24/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ALLR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALLR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALLR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

              TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that IP Australia, the Australian Government agency that administers intellectual property rights in the country, has formally accepted the Company's patent application for its DRP® companion diagnostic specific to stenoparib. The acceptance covers 40 claims and marks a key step in Allarity's

      6/30/25 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

               TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today announced that the second patient has been dosed in its new Phase 2 clinical trial protocol evaluating stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. Commenting on the development, Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, stated: "We are pleased to see the second patient enrolled so soon after the trial's launch. This pace of enrollment suggests a

      6/27/25 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Announces Changes to Board of Directors

          TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acqua

      6/11/25 4:05:00 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Vazzano Joseph Walter

      4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

      1/24/25 8:10:53 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Director Benjamin Laura

      4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

      1/24/25 8:09:04 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Director Mclaughlin Gerald W.

      4/A - Allarity Therapeutics, Inc. (0001860657) (Issuer)

      1/24/25 8:07:13 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    SEC Filings

    See more
    • Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

      6/30/25 8:00:28 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form RW filed by Allarity Therapeutics Inc.

      RW - Allarity Therapeutics, Inc. (0001860657) (Filer)

      6/24/25 8:07:10 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

      6/17/25 4:21:00 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Leadership Updates

    Live Leadership Updates

    See more
    • Allarity Therapeutics Announces Changes to Board of Directors

          TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acqua

      6/11/25 4:05:00 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

        Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent operational highlights. "This quarter's progress marks a steady period of advancement for Allarity as we have maintained a strong cash position, achieved record patient duratio

      11/14/24 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program

      Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company's clinical development programsEli Lilly and Celgene veteran Jose Iglesias, M.D., joins as Consultant Chief Medical Officer to drive the stenoparib program toward regulatory approvalFormer President of Novo Nordisk's U.S. Operations, Jesper Høiland, appointed as Strategic Advisor to guide strategic initiatives and optimize commercial potential Boston (October 3, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced seve

      10/3/24 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Financials

    Live finance-specific insights

    See more
    • Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

      - Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024. "The s

      5/14/24 4:01:00 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics Reports Third Quarter 2022 Financial Results

      Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. ("Allarity" or the "Company"), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity's cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expenses: Research and Development (R&D) expenses were $3.0 million for the three months ended September 30, 2022, as compared to $1.4 million for the three months ended September 30, 2021. G&A Expenses:

      11/15/22 4:01:00 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

      Press release        Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity's DRP® companion diagnostics Allarity has submitted a new drug application (NDA) for the U.S. approval of dovitinib in renal cell carcinoma (RCC) together with the Dovitinib-DRP® companion diagnostic Cambridge, MA U.S.A. (January 3, 2022) — Allarity Therapeutics, Inc. (NASDAQ:ALLR) ("Allarity" or the "Company"), a clinical-stage biopharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Oncoheroes Biosciences, Inc. ("Oncoheroes"), a clini

      1/3/22 8:00:00 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Allarity Therapeutics Inc.

      SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)

      11/13/24 9:24:34 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Allarity Therapeutics Inc.

      SC 13G - Allarity Therapeutics, Inc. (0001860657) (Subject)

      8/29/24 3:57:47 PM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allarity Therapeutics Inc. (Amendment)

      SC 13G/A - Allarity Therapeutics, Inc. (0001860657) (Subject)

      2/12/24 9:52:15 AM ET
      $ALLR
      Biotechnology: Pharmaceutical Preparations
      Health Care